Please ensure Javascript is enabled for purposes of website accessibility

U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment

By Cory Renauer - Feb 25, 2020 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

For the first time on U.S. soil, a patient with COVID-19 has been treated with the antiviral drug remdesivir.

On Tuesday, officials from the National Institute of Health (NIH) announced the initiation of a clinical trial in which patients in U.S. hospitals with confirmed COVID-19 infections will be given Gilead Sciences' (GILD 0.82%) drug remdesivir. 

What we know 

The first clinical trial participant was an American currently at the Nebraska Medical Center in Omaha, who had been quarantined with other infected passengers from the Diamond Princess cruise ship.

Scientist examining a flask of blue stuff.

Image source: Getty Images.

While we can be fairly certain the first trial participant won't be in a hurry to take another cruise, that's really all we know about this person at the moment. The NIH and Gilead Sciences will most likely randomize patients into groups receiving remdesivir or a placebo, so don't discount remdesivir's potential as a COVID-19 treatment if you don't see news of about the rapid recovery from that first enrolled U.S. patient in the next couple of days.

Health officials at the China-Japan Friendship Hospital and other centers in Hubei province have already started a clinical trial testing remdesivir in patients infected with SARS-CoV-2, the coronavirus that causes COVID-19. Anecdotal reports about those who have been treated with remdesivir for the illness have been positive. But it will be impossible to properly gauge the value of the treatment until we can actually compare outcomes between significant numbers of patients who actually received the experimental antiviral drug and those who just think they did.

No longer a theoretical problem

Also on Tuesday, Dr. Nancy Messonnier, director of the National Center for Immunization and Respiratory Diseases Centers at the U.S. Centers for Disease Control, asked the American public to prepare for significant disruption to their daily lives.

So far, 80,238 people have been diagnosed with COVID-19, and 53 of those cases have been confirmed in the U.S. With numbers like these, further spread across the country is to be expected.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.96 (0.82%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.